Form 4: Vaxcyte Director Halley Gilbert Reports Stock and Option Awards

Director Halley E. Gilbert reports acquisition of common stock and stock options in Vaxcyte, Inc.

Summary

• On June 6, 2024, Halley E. Gilbert, a director of Vaxcyte, Inc. (PCVX), reported the acquisition of 1,550 shares of common stock underlying restricted stock units (RSUs) and options to purchase 7,250 shares of common stock.
• The RSUs will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• The options will vest monthly and fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Following the transaction, Gilbert directly owns 7,175 shares of common stock and options to purchase 7,250 shares of common stock.
• A Power of Attorney was executed on June 7, 2024, granting certain individuals the authority to execute and file Forms 3, 4, and 5 on behalf of Halley Gilbert.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants to a director. While insider ownership can be a positive signal, this is a routine disclosure.

Positives

• The acquisition of stock and options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of RSUs and options is contingent on continued service.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and management's stake in the company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to increased insider ownership.

Key Dates